Grace Therapeutics, Inc. (GRCE)

Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update

Grace Therapeutics Announces $10 Million Private Placement

Grace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug Administration

Grace Therapeutics (NASDAQ:GRCE) Trading Down 2.5% – Here’s What Happened

Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update

GRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

GRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

GRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

GRCE INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Grace Therapeutics, Inc.

Grace Therapeutics: Assessing The Path Forward For GTx-104

GRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law Firm